Additional file 1 of Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

Additional file 1: Table S1. Clinical factors included for primary and sensitivity analyses comparing liso-cel with tisagenlecleucel. Table S2. Comparison of clinical factors before and after MAIC for primary and sensitivity analyses of PFS in TRANSCEND and JULIET. Table S3. Comparison of clinical factors before and after MAIC for primary and sensitivity analyses of CR in TRANSCEND and JULIET. Table S4. Comparison of clinical factors before and after MAIC for primary and sensitivity analyses of ORR in TRANSCEND and JULIET. Table S5. Comparison of clinical factors before and after MAIC for safety analysis in TRANSCEND and JULIET.